245 related articles for article (PubMed ID: 9857110)
1. Relationship of serum levels of interleukin-6, soluble interleukin-6 receptor and tumour necrosis factor receptors to the acute-phase protein response in advanced pancreatic cancer.
Barber MD; Fearon KC; Ross JA
Clin Sci (Lond); 1999 Jan; 96(1):83-7. PubMed ID: 9857110
[TBL] [Abstract][Full Text] [Related]
2. Circadian fluctuations of melatonin, tumor necrosis factor-alpha and its soluble receptors in the circulation of patients with advanced gastrointestinal cancer.
Muc-Wierzgon M; Nowakowska-Zajdel E; Zubelewicz B; Wierzgon J; Kokot T; Klakla K; Szkilnik R; Wiczkowski A
J Exp Clin Cancer Res; 2003 Jun; 22(2):171-8. PubMed ID: 12866566
[TBL] [Abstract][Full Text] [Related]
3. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity.
Gabay C; Cakir N; Moral F; Roux-Lombard P; Meyer O; Dayer JM; Vischer T; Yazici H; Guerne PA
J Rheumatol; 1997 Feb; 24(2):303-8. PubMed ID: 9034987
[TBL] [Abstract][Full Text] [Related]
4. TNF-alpha, IL-6 and their soluble receptor serum levels and secretion by neutrophils in cancer patients.
Jabłońska E; Kiluk M; Markiewicz W; Piotrowski L; Grabowska Z; Jabłoński J
Arch Immunol Ther Exp (Warsz); 2001; 49(1):63-9. PubMed ID: 11266093
[TBL] [Abstract][Full Text] [Related]
5. Soluble cytokine receptors in renal vasculitis and lupus nephritis.
Tesar V; Jirsa M; Zima T; Kalousová M; Bartunková J; Stejskalová A; Dostál C; Zabka J
Med Sci Monit; 2002 Jan; 8(1):BR24-9. PubMed ID: 11782670
[TBL] [Abstract][Full Text] [Related]
6. Tumor necrosis factor alpha, its soluble receptor I, and -308 gene promoter polymorphism in patients with rheumatoid arthritis with or without amyloidosis: implications for the pathogenesis of nephropathy and anemia of chronic disease in reactive amyloidosis.
Maury CP; Liljeström M; Laiho K; Tiitinen S; Kaarela K; Hurme M
Arthritis Rheum; 2003 Nov; 48(11):3068-76. PubMed ID: 14613268
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-1 receptor antagonist, soluble tumor necrosis factor-alpha receptor type I and II, and soluble E-selectin serum levels in multiple sclerosis patients receiving weekly intramuscular injections of interferon-beta1a.
Perini P; Tiberio M; Sivieri S; Facchinetti A; Biasi G; Gallo P
Eur Cytokine Netw; 2000 Mar; 11(1):81-6. PubMed ID: 10705303
[TBL] [Abstract][Full Text] [Related]
8. Analysis of tumor necrosis factor-alpha, interleukin-6, interleukin-1beta, soluble tumor necrosis factor receptors I and II, interleukin-6 soluble receptor, interleukin-1 soluble receptor type II, interleukin-1 receptor antagonist, and protein in the synovial fluid of patients with temporomandibular joint disorders.
Kaneyama K; Segami N; Sun W; Sato J; Fujimura K
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2005 Mar; 99(3):276-84. PubMed ID: 15716832
[TBL] [Abstract][Full Text] [Related]
9. Elevated serum levels of the type I and type II receptors for tumor necrosis factor-alpha as predictive factors for ARF in patients with septic shock.
Iglesias J; Marik PE; Levine JS;
Am J Kidney Dis; 2003 Jan; 41(1):62-75. PubMed ID: 12500222
[TBL] [Abstract][Full Text] [Related]
10. Hepatic regeneration induces transient acute phase reaction: systemic elevation of acute phase reactants and soluble cytokine receptors.
Fulop AK; Pocsik E; Brozik M; Karabelyos C; Kiss A; Novak I; Szalai C; Dobozy O; Falus A
Cell Biol Int; 2001; 25(7):585-92. PubMed ID: 11448096
[TBL] [Abstract][Full Text] [Related]
11. Tumor necrosis factor-alpha-induced insulin resistance may mediate the hepatitis C virus-diabetes association.
Knobler H; Zhornicky T; Sandler A; Haran N; Ashur Y; Schattner A
Am J Gastroenterol; 2003 Dec; 98(12):2751-6. PubMed ID: 14687828
[TBL] [Abstract][Full Text] [Related]
12. Dynamics of diurnal changes in serum concentration of TNF-alpha soluble receptors in gastrointestinal cancer patients.
Muc-Wierzgoń M; Baranowski MM; Madej K; Wierzgoń J; Kokot T; Brodziak A
J Biol Regul Homeost Agents; 2000; 14(3):204-8. PubMed ID: 11037054
[TBL] [Abstract][Full Text] [Related]
13. Increase of anti-inflammatory cytokines in patients with esophageal cancer after perioperative treatment with G-CSF.
Hübel K; Mansmann G; Schäfer H; Oberhäuser F; Diehl V; Engert A
Cytokine; 2000 Dec; 12(12):1797-800. PubMed ID: 11097751
[TBL] [Abstract][Full Text] [Related]
14. Soluble TNF and IL-2 receptors in patients with breast cancer.
Tesarová P; Kvasnicka J; Umlaufová A; Homolková H; Jirsa M; Tesar V
Med Sci Monit; 2000; 6(4):661-7. PubMed ID: 11208388
[TBL] [Abstract][Full Text] [Related]
15. Poly-C specific ribonuclease activity correlates with increased concentrations of IL-6, IL-8 and sTNFR55/sTNFR75 in plasma of patients with acute pancreatitis.
Naskalski JW; Kusnierz-Cabala B; Panek J; Kedra B
J Physiol Pharmacol; 2003 Sep; 54(3):439-48. PubMed ID: 14566081
[TBL] [Abstract][Full Text] [Related]
16. Relation between pro- and anti-inflammatory cytokines and the production of nitric oxide (NO) in severe sepsis.
Groeneveld PH; Kwappenberg KM; Langermans JA; Nibbering PH; Curtis L
Cytokine; 1997 Feb; 9(2):138-42. PubMed ID: 9071565
[TBL] [Abstract][Full Text] [Related]
17. Release of soluble tumor necrosis factor receptors from polymorphonuclear cells of breast cancer patients.
Jabłońska E; Pietruska Z
Arch Immunol Ther Exp (Warsz); 1997; 45(5-6):449-53. PubMed ID: 9437501
[TBL] [Abstract][Full Text] [Related]
18. Increased serum levels of soluble tumor necrosis factor a-receptors in patients undergoing partial liver resection.
Schroder J; Gallati H; Kremer B
Hepatogastroenterology; 1998; 45(23):1807-12. PubMed ID: 9840152
[TBL] [Abstract][Full Text] [Related]
19. Serum values of tumour necrosis factor-alpha and of soluble tumour necrosis factor-R55 in melanoma patients.
Ocvirk J; Stabuc B; Rudolf Z; Galvani V; Curin-Serbec V
Melanoma Res; 2000 Jun; 10(3):253-8. PubMed ID: 10890379
[TBL] [Abstract][Full Text] [Related]
20. Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM)) and soluble interleukin-6 (IL-6) receptor (sIL-6R) in patients with multiple myeloma.
Urbańska-Ryś H; Wiersbowska A; Stepień H; Robak T
Eur Cytokine Netw; 2000 Sep; 11(3):443-51. PubMed ID: 11022130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
